The mutations of F-box protein 7 (FBXO7) gene (T22M, R378G and R498X) are associated with a severe form of autosomal recessive juvenile-onset Parkinson's disease (PD) (PARK 15). Here we demonstrated that wild-type (WT) FBXO7 is a stress response protein and it can play both cytoprotective and neurotoxic roles. The WT FBXO7 protein is vital to cell mitophagy and can facilitate mitophagy to protect cells, whereas mutant FBXO7 inhibits mitophagy. Upon stress, the endogenous WT FBXO7 gets up-regulated, concentrates into mitochondria and forms FBXO7 aggregates in mitochondria. However, FBXO7 mutations aggravate deleterious FBXO7 aggregation in mitochondria. The FBXO7 aggregation and toxicity can be alleviated by Proline, glutathione (GSH) and coenzyme Q10, whereas deleterious FBXO7 aggregation in mitochondria can be aggravated by prohibitin 1 (PHB1), a mitochondrial protease inhibitor. The overexpression of WT FBXO7 could lead to FBXO7 protein aggregation and dopamine neuron degeneration in transgenic Drosophila heads. The elevated FBXO7 expression and aggregation were identified in human fibroblast cells from PD patients. FBXO7 can also form aggregates in brains of PD and Alzheimer's disease. Our study provides novel pathophysiologic insights and suggests that FBXO7 may be a potential therapeutic target in FBXO7-linked neuron degeneration in PD.
Introduction
Parkinson's disease (PD) is a chronic and progressive disease that is caused primarily by the loss of dopaminergic neurons in the substantia nigra (SN) (1) (2) (3) . The mechanisms underlying the selective and progressive loss of nigral dopaminergic neurons in PD have not been fully elucidated. Although most individuals suffer from sporadic PD, about 10-15% of PD patients have inherited disease (familial form of PD) (4) . Variants or mutations of at least six PD-related genes [such as α-synuclein (α-syn) and PAR-KIN] have been implicated in the pathogenesis of familial PD (5) (6) (7) (8) (9) (10) (11) . Recently, mutations in the F-box protein 7 gene (FBXO7) have been associated with a severe form of autosomal recessive juvenile-onset levodopa-responsive parkinsonism (PARK15) with rapid progressive parkinsonism and pyramidal signs (12, 13) . At present, at least 18 PARK15 patients from 5 families have been reported to carry FBXO7 mutations that include a homozygous nonsense mutation (R498X), a compound heterozygous mutation (T22M) (12) and a homozygous R378G mutation (14) . Besides rigidity and bradykinesia, other features include dementia or cognitive decline, abnormal eye movement, gait unsteadiness and early posture imbalance (13) . The wide clinical spectrum associated with FBXO7 mutations suggests that FBXO7 mutationinduced pathological alterations are unlikely to be restricted only to dopaminergic neurons in SN.
FBXO7 is a member of F-box-containing protein family defined by the presence of an F-box domain, which binds with Skp1 protein (15, 16) . Through this interaction, F-box proteins are recruited as components of Skp-Cullin-F-box complex, an E3 ubiquitin ligase (17) (18) (19) . FBXO7 is mainly expressed in the cerebral cortex, globus pallidum and SN, and to a lesser extent in the hippocampus and cerebellum (20) . FBXO7 has been reported to catalyze the ubiquitination of HURP/DLG7, a regulator of mitotic spindle assembly, marking the protein for degradation by the proteasome (21) . FBXO7 also promotes ubiquitination of cIAP1, an inhibitor of apoptosis family member that regulates canonical and non-canonical NF-κB signaling (22) . Overexpression of FBXO7 in immortalized fibroblasts augments the levels of Cdk6 bound to D-type cyclins and led to transformation (23, 24) .
There is limited information on the pathophysiologic mechanism of FBOX7-linked neuronal degeneration in PD. A recent study found alterations of subcellular localization and protein expression levels of endogenous FBXO7 proteins in lymphoblastoids and fibroblasts of PARK15 patients with FBXO7 mutations (20) . Furthermore, mutant FBXO7 protein has decreased stability compared with wild-type (WT) FBXO7 (20) . Another recent study reported that FBXO7 might be involved in mitochondrial quality maintenance via interaction with PINK1 and PARKIN (25) . However, many questions regarding FBXO7 mutations in PD remain unanswered. In particular, it is still unclear if WT FBXO7 has neuroprotective functions and how FBXO7 mutations contribute to neuronal degeneration in PD. To address these knowledge gaps related to FBXO7, here we allude for the first time that FBXO7 is a stress response protein. The WT FBXO7 has paradoxical protective and toxic roles. However, PD-linked FBXO7 mutations lead to loss of protective functions and aggravation of toxic effects of WT FBXO7. The PD-related FBXO7 mutants can aggravate protein aggregates in mitochondria, impair mitochondrial function, promote reactive oxygen species (ROS) production and decrease cell viability. Our findings suggest that FBXO7 may be a potential therapeutic target in FBXO7-linked neuron degeneration in PD.
Results

WT FBXO7 have cytoprotective functions, while PD-linked FBXO7 mutants are toxic
Knocking down of endogenous WT FBXO7 in dopaminergic PC12 cells by FBXO7 shRNA transfection led to decreased PC12 cell viability even in the absence of stress ( Fig. 1A and B) . Similarly, knocking down of FBXO7 expression in HEK cells can impair HEK cell viability in the absence of stress and sensitized cells to H 2 O 2 -induced toxicity ( Fig. 1C-E) . Next, we transfected human HEK (Fig. 1F ) and dopaminergic neuronal SK-N-SH cells ( Fig. 1H ) with GFP-tagged human isoform1 (WT1), isoform 2 (WT2) WT and 3 FBXO7 mutants (T22M, R378G and R498X). The overexpressed WT2 and T22M mutant FBXO7 in HEK cells showed decreased protein levels compared with WT1 and other FBXO7 mutants ( Fig. 1F and G) . WT1, WT2, R378G and R498X FBXO7 proteins localized mainly in nucleus ( Fig. 1H and I ). However, T22M FBXO7 localized primarily in cytoplasm ( Fig. 1H and I ). WT FBXO7 can protect against DA or H 2 O 2 induced toxicity, whereas mutant FBXO7 protein aggravated stress-induced toxicity ( Fig. 1J and K) .
Mutations of FBXO7 promote deleterious aggregation of FBXO7 proteins
We found that overexpressed WT and mutant FBXO7 in human dopaminergic SK-N-SH cells could form FBXO7 protein aggregates (insoluble FBXO7 proteins) ( Fig. 2A and B) . Mutant FBXO7 formed more aggregates than WT FBXO7 ( Fig. 2A-G) . Most of FBXO7 aggregates were observed in cytoplasm (Fig. 2B) . The FBXO7 protein aggregate formation was time-and stress-dependent ( Fig. 2A , E-G). Stressing of cells significantly promoted FBXO7 aggregation (Fig. 2F) . Furthermore, FBXO7 aggregation impaired cell viability, especially when transfected with mutant FBXO7 ( Fig. 2H and I ). However, FBXO7 aggregation-and FBXO7 overexpression-induced cell viability impairment can be alleviated by glutathione (GSH) and Proline treatments (Fig. 2G , H, L and M). The Proline is not a reductant but reported to have protein aggregation inhibiting capacity, which is different from GSH ( Fig. 2N) (30, 31) . On the contrary, the FBXO7 aggregation can be aggravated by MG132 proteasome inhibition, but not by 3-MA autophagy inhibition (Fig. 2J) . The mono-ubiquitination of FBXO7 promoted FBXO7 aggregation significantly, which corroborated a recent report that mono-ubiquitination of α-syn promotes aggregate formation of α-syn (Fig. 2K) (32) .
FBXO7 mutants promoted aggregation of WT FBXO7 and WT PARKIN ( Fig. 2O and P). Cells were co-transfected with Myctagged WT1 FBXO7 together with GFP-tagged WT1 FBXO7 or mutant R378G FBXO7. We showed that GFP-tagged mutant R378G FBXO7 promoted aggregation of Myc-tagged WT1 FBXO7 (Fig. 2O) . However, GFP-tagged WT1 FBXO7 was unable to affect aggregation of Myc-tagged WT1 FBXO7 (Fig. 2O) . Similarly, GFP-tagged mutant R378G FBXO7 also promoted aggregate formation of WT PARKIN (Fig. 2P ).
Neurotoxins induced aggregate formation of endogenous WT FBXO7
Next, we studied the aggregation of endogenous WT FBXO7 in human dopaminergic neuronal SK-N-SH cells and mice primary neurons (Fig. 3) . We found that challenging dopaminergic SK-N-SH cells with DA, Rotenone and H 2 O 2 could induce dose-and time-dependent FBXO7 aggregation (Fig. 3A-H) . Conversely, the amount of soluble WT FBXO7 in cells decreased accordingly ( Fig. 3A-H) . Stress-induced endogenous FBXO7 aggregate formation could also be observed in HEK cells (Supplementary Material, Fig. S1 ). However, quantitative real-time RT-PCR analysis demonstrated that expression of FBXO7 increased with time after stress challenges (Fig 3J) . In HEK and dopaminergic SHSY-5Y cells, the stress-induced up-regulation of FBXO7 expression levels was similar to those of FBXO7 transfection-induced alternations (Supplementary Material, Fig. S2 ). Both mice and human FBXO7 proteins formed aggregates after H 2 O 2 challenge (Fig. 3I) . The protein aggregates of mice and human FBXO7 co-localized with β-tubulin near nucleus (Fig. 3I) . This indicated the localization of FBXO7 aggregate in aggresomes, suggesting the attempt by the cells to clear WT FBXO7 aggregate via aggresome-autophagy pathway.
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PD gene mutations induced endogenous WT FBXO7 aggregate formation
We found that the level of ROS was elevated in our LRRK2 stable transfected dopaminergic SH-SY-5Y cells, especially in mutant G2019S LRRK2 cells (Fig. 3O ). Furthermore, the expression level of FBXO7 protein was increased and the amount of insoluble FBXO7 was enhanced in LRRK2 stable cells, especially in G2019S mutant cells (Fig. 3K-N) . However, the increased ROS levels, up-regulated FBXO7 expressions and increased FBXO7 aggregation in LRRK2 stable cells were improved by GSH and coenzyme Q10 (COQ10) treatment (Fig. 3K-O) . The increased FBXO7 expression and FBXO7 aggregation were also found in LRRK2 transgenic mice brains ( Fig. 3P and Q) .
In human skin fibroblasts from PD patients with or without mutations of PD-linked genes, we found that the FBXO7 protein levels were increased in the PD fibroblasts ( Fig. 4A and B) . The increased expression of FBXO7 in PD fibroblast cells was alleviated by GSH or COQ10 treatment ( Fig. 4C-E) . The amount of insoluble FBXO7 in PD fibroblast cells was also increased, which was reduced by GSH or COQ10 treatment ( Fig. 4F and G) . GSH is a reductant with strong reducing potency, whereas COQ10 (oxidized form) is not (Fig. 4H) . However, they can both inhibit FBXO7 
FBXO7 aggregation in brains of PD and Alzheimer's disease patients
We checked the FBXO7 aggregation in postmortem human brain samples of PD and Alzheimer's disease (AD) patients ( Fig. 4I and J) . In the cortex of PD patients, the amounts of soluble and insoluble FBXO7 were up-regulated, compared with those of aged controls (Fig. 4I ). In the cortex samples of AD patients, the levels of soluble FBXO7 did not alter much. However, the amount of insoluble FBXO7 increases significantly in gray matter and white matter of AD patients, compared with those of aged controls (Fig. 4J ). These findings suggest that FBXO7 aggregation may be linked to neuron degeneration in both PD and AD.
Overexpression of WT FBXO7 leads to FBXO7 protein aggregation and dopaminergic neuron degeneration in Drosophila
We generated transgenic Drosophila models overexpressing human WT1 FBXO7 controlled by tissue-specific UAS-GAL4 system. Two transgenic fly lines were created: W;P{UAS-Fbxo7.WT} (II) and W;P{UAS-Fbxo7.WT}attp.ZH-51C(II). We found that overexpression of WT FBXO7 in dopaminergic neurons did not have any significant influence on fly life span (Fig. 5A ). However, after 30-40 days culture, overexpression of WT1 FBXO7 in Drosophila dopaminergic neurons led to locomotor deficits in flight and climbing ability of flies (Fig. 5B) . Overexpression of human WT FBXO7 in fly dopaminergic neurons for 40 days induced dopaminergic neuron loss, especially in PPM1/2 and PPM3 dopaminergic neuron clusters ( Fig. 5D and F) . Furthermore, overexpression of WT FBXO7 protein in fly heads for 40 days led to FBXO7 protein aggregation (Fig. 5C ). The overexpression of WT1 FBXO7 for 40 days led to swelling of muscle mitochondria, broken mitochondria cristae and accumulated high density materials in the swollen mitochondria (Fig. 5E ).
Stress-induced translocation of FBXO7 from nucleus into mitochondria and formation of deleterious FBXO7 aggregates
We found that endogenous FBXO7 protein could localize to mitochondria in the absence of stress ( However, lesser amounts of mutant FBXO7 proteins were localized to mitochondria, compared with WT1 FBXO7 (Fig. 6B -G, J). Compared with (overexpressed or endogenous) WT FBXO7, H 2 O 2 challenge led to reduced soluble FBXO7 mutants (R378G and R498X) in both mitochondria and nucleus ( Fig. 6C-F) . The H 2 O 2 challenge also significantly promoted aggregation of mutant FBXO7 in whole cell, nucleus as well as in mitochondria ( Fig. 6D and E) . Next, we investigated FBXO7 aggregation in mitochondria in the presence of overexpressed prohibitin 1 (PHB1). Co-transfection of PHB1 with WT1 or mutant R498X FBXO7 into HEK cells led to increased levels of soluble and insoluble FBXO7 in whole cell and mitochondria, especially the increased amount of insoluble fraction of FBXO7 proteins in mitochondria ( Fig. 6H and I) . However, PHB1 did not change the composition of soluble and insoluble FBXO7 in nucleus (Fig. 6J) . Co-expression of PHB1 aggravated cell viability impairment, especially mutant R498X FBXO7 (Fig. 6K ).
FBXO7 aggregation in mitochondria impairs mitochondria integrity and enhances ROS production
We found that FBXO7 aggregates co-localized with ROS indicator RedoxSensor RCC-1 (Fig. 7A) and WT1 or mutant R498X FBXO7 aggregates co-localized well with TOM20 (a mitochondria marker) and 4-HNE (a marker for lipid peroxidation) (Fig. 7B and C) . The overexpression of mutant FBXO7 decreased mitochondrial membrane potential in a time-dependent manner (Fig. 7D) . The overexpression of WT FBXO7 for 1 day increased the mitochondrial membrane potential (Fig. 7D) . However, the increased mitochondrial membrane potential of cells transfected with WT FBXO7 was reversed after 3 days' culture (Fig. 7D ). These observations suggest that WT FBXO7 can be protective to cells, but longer time exposure to high level of WT FBXO7 may lead to FBXO7 aggregation in mitochondria. Next, we quantitatively detected the ROS levels in cells with our newly developed procedure using RedoxSensor RCC-1 dye (Fig. 7E) . We found that overexpressing mutant FBXO7 could enhance ROS levels ( Fig. 7F and G) . Overexpression of WT FBXO7 for 2 and 3 days (longer time exposure) also promoted ROS generation (Fig. 7G ).
FBXO7 mutants inhibit mitophagy
Knocking down of endogenous FBXO7 expression impaired FCCP-induced mitophagy ( Fig. 8A and B) . We used NAO-Hoechst dual dyes staining protocol and western blot analysis of the content of cytochrome c to quantitatively monitor mitophagy process (29) . We found that overexpression of WT PARKIN promoted FCCP (20 µ)-induced mitophagy (Fig. 8E) . The mutant PARKIN inhibited FCCP-induced mitophagy (Fig. 8E) . However, overexpression of WT FBXO7 facilitated mitophagy either in the presence or in the absence of FCCP (Fig. 8F, G and I) . Overexpression of mutant FBXO7 proteins inhibited FCCP-induced mitophagy (Fig. 8F, H and J) . Recent findings reported that WT FBXO7 can rescue PARKIN mutation-induced mitophagy defects (25) . Our data confirmed that WT FBXO7 promotes mitophagy, whereas mutations of FBXO7 lead to inhibition of mitophagy process.
Discussion
In this study, we demonstrated that FBXO7 protein is a stress response protein and that stress-induced up-regulation of transient WT FBXO7 expression can be protective to cells. However, mutant FBXO7 proteins aggravate neurotoxin-induced cell demise. Cellular stress can promote FBXO7 proteins' deleterious protein aggregate formation, especially in mitochondria. The PD-linked FBXO7 mutations facilitate FBXO7 aggregates formation in mitochondria, impair mitochondria function, promote ROS generation and decrease cell viability. WT FBXO7 facilitates cytoprotective mitophagy, whereas PD-linked FBXO7 mutations inhibit mitophagy process. The PD-linked mutations of FBXO7 lead to loss of protective functions and aggravation of toxic effects of WT FBXO7.
A role for mitochondria dysfunction in the pathogenesis of PD is well recognized (30) . The mitochondria are recognized as dynamic and mobile organelles that constantly undergo membrane Human (31) . These processes help to maintain a steady pool of healthy mitochondrial essential for energy production and beyond (31) . Mitophagy is a process where mitochondria are targeted for degradation via autophagy pathway (32) . The impaired mitophagy process and subsequent delayed clearance of dysfunctional mitochondria in cell can contribute to decreased ATP production, ROS generation and finally dopaminergic neuron degeneration in PD (30) . Mitophagy is regulated by PINK1 and PARKIN pathway (33) . A recent report demonstrates that FBXO7 binds with PARKIN and may be involved in the translocation of PARKIN to damaged mitochondria (25) . Here, we demonstrated that FBXO7 may interact with key FBXO7 targets in mitochondria to modulate mitophagy process. Further studies to identify FBXO7 mitochondrial targets will further unravel the mechanism of FBXO7-modulated mitophagy.
The WT FBXO7 can be protective but FBXO7 can form deleterious protein aggregates. Recently, the FBXO7 immunoreactivity was reported to be detected in large proportions of insoluble α-syn-positive inclusions (20) . The similar scenario has been reported in α-syn and SOD1. Both WT α-syn and SOD1 have protective functions (34, 35) . However, WT and mutant α-syn can both form protein aggregate, which predispose to dopaminergic neuron degeneration in PD (36) . The aggregation of mutant SOD1 is relevant to familial form of amyotrophic lateral sclerosis (ALS) (37, 38) . However, oxidative stress-induced misfolding and aggregation of WT SOD1 is implicated in the pathogenesis of sporadic ALS (39). We showed that FBXO7 can concentrate into mitochondria under stress and form deleterious protein aggregate in mitochondria, leading to cell viability impairment. Maintaining protein homeostasis involves an elaborate protein quality control system, consisting of chaperones and proteases in the mitochondria (40) (41) (42) . The highly conserved mitochondrial proteases can clear and remove non-assembled, misfolded and aggregated proteins to maintain protein homeostasis in mitochondria (40) . Impairment of m-ATP mitochondria proteases can contribute to neuron degeneration (43, 44) . PHB1 is an endogenous m-ATP protease inhibitor, located in the inner membrane of mitochondria (45) . We found for the first time that PHB1 promoted deleterious FBXO7 aggregation in mitochondria. Thus, PHB1 may become a therapeutic target to alleviate FBXO7-linked neuron degeneration in PD. Our observations were corroborated by recent studies that showed that IMD-019064 and FL40, new small molecular PHB1 inhibitors, can protect dopaminergic neurons in both in vitro and in vivo PD models (MPP+-induced neurotoxicity) and traumatic brain injury (38) .
On the other hand, it is reported that small molecules such as the anti-oxidant pyrroloquinoline quinone (PQQ) prevents the toxic amyloid fibril formation of α-syn, Aβ1-42 and mouse prion protein in vitro (46, 47) . Furthermore, PQQ-modified α-syn prevents the amyloid formation of intact α-syn (46). In our current different days, mitochondria membrane potential was analyzed using TRAM dye. Cells transfected with GFP were set as control and the mitochondrial potential of GFP-transfected cells was set as 100%. *, at least P < 0.05, compared with the mitochondrial potential of cells transfected with GFP for 1, 2 or 3 days respectively. # , P < 0.05, compared with the mitochondrial potential of cells transfected with the same FBXO7 protein for 1 day, respectively. (E) Quantitative analysis of ROS level in cells challenged with H2O2. HEK cells were challenged with different concentration of H2O2 for 3 h before ROS levels were monitored using RedoxSensor Red CC-1 dye.
Cells without challenge were set as control and the ROS level of control cells was set as 100%. *, at least P < 0.01, compared with the ROS level of cells without challenge. (F) Influence on cell ROS levels by overexpression of GFP-tagged WT and mutant FBXO7 proteins. After transfection of HEK cells with GFP or GFP-tagged WT and mutant FBXO7 overnight, ROS levels in cells were analyzed using RedoxSensor Red CC-1 dye. Cells transfected with GFP were set as control and the ROS level of control cells was set as 100%. *, at least P < 0.05, compared with the ROS level of GFP-transfected cells. (G) Time-dependent influence on cell ROS level by overexpression of GFPtagged WT and mutant FBXO7 proteins. After transfection of HEK cells with GFP or GFP-tagged WT and mutant R498X FBXO7 for 1, 2 and 3 days respectively, ROS level was analyzed using RedoxSensor Red CC-1 dye. Cells transfected with GFP were set as control and the ROS level of control cells for 1 day was set as 100%. *, at least P < 0.05, study, we showed that Proline, GSH and COQ10 could alleviate FBXO7 mutation and stress-induced accumulation of deleterious FBXO7 aggregation. These small molecules may inhibit FBXO7 aggregation and benefit FBXO7-linked neuron degeneration in PD.
We hypothesize that FBXO7 may interact with its various binding partners in cytosol, mitochondria and nucleus. In cytosol and mitochondria, FBXO7 may interact with chaperones to prevent the self-aggregation of FBXO7 proteins. FBXO7 mutations may alter FBXO7 structure, leading to impaired binding capacity with chaperone proteins and aggregation formation. Under stress, the up-regulated FBXO7 level may disturb the interaction between FBXO7 and chaperone. This may contribute to stressinduced FBXO7 aggregation. Thus, searching for key FBXO7 binding partners, especially chaperones in mitochondria, will have therapeutic significance. We find that T22M mutant FBXO7 is mainly localized to cytoplasm, which is a different primary subcellular location compared with WT, R378G and R498X FBXO7 proteins. It is possible that mutations in different domains of FBXO7 cause FBXO7 proteins aggregation via different pathways, or the different FBXO7 domains interact and regulate each other. These possibilities warrant further investigations. The potential pathological links among FBXO7 aggregation, mitochondria impairment, ROS generation as well as mitophagy modulation are illustrated in Scheme 1.
In summary, our study demonstrated that FBXO7 is a stress response protein and upon stress, the endogenous WT FBXO7 gets up-regulated, concentrates into mitochondria and forms FBXO7 aggregates in mitochondria. However, FBXO7 mutations Scheme 1. Potential mechanisms for FBXO7-linked neurodegeneration. (A) FBXO7-linked pathogenesis involving FBXO7 aggregation, mitochondrial impairment, ROS production and deregulation of mitophagy process. FBXO7 mutation can lead to increased aggregation of FBXO7, especially in mitochondria. The FBXO7 aggregate that formed in mitochondria will impair mitochondrial integrity, leading to decreased ATP production and increased ROS production. The enhanced ROS production will facilitate FBXO7 aggregation. Therefore, an adverse amplification loop was proposed. Besides ROS production, mutant FBXO7 proteins can inhibit mitophagy process and hence impair the clearance of damaged mitochondria via autophagy process, aggravating the positive feedback loop. The positive feedback loop can be exacerbated by pathological factors, such as factors that inhibit UPS, aggravate oxidative stress or inhibit mitochondria. However, ROS scavengers, protein aggregate inhibitors and mitophagy inducers may break the debilitating cycle and have potential therapeutic significance against FBXO7-linked dopaminergic neuron degeneration in PD. (B) The potential mechanism of ROS facilitated FBXO7 aggregation. The increased ROS may directly oxidize FBXO7, thus promoting misfold and FBXO7 aggregation. Furthermore, ROS challenge can up-regulate FBXO7 expressions. ROS can also inhibit proteasome activities. Thus, the increased FBXO7 expression and impaired FBXO7 clearance capacity under stress will favor FBXO7 aggregation. Subsequently, the accumulated FBXO7 aggregation and increased ROS levels in cells will impair mitochondrial integrity. This will lead to more ROS production and decreased cell ATP production. The decreased ATP production can inhibit UPS function and impair clearance of FBXO7 aggregate in cells. Finally, these complicated pathological events may interact and converge to contribute to FBXO7 aggregation. aggravate deleterious FBXO7 aggregation in mitochondria. The elevated FBXO7 expression and aggregation were identified in human fibroblast cells from PD patients. FBXO7 can also form aggregate in patient brains of PD and AD. Our study provides novel pathophysiologic insights and suggests that FBXO7 may be a potential therapeutic target in FBXO7-linked neuron degeneration in PD.
Materials and Methods
Plasmids and vectors
Human FBXO7-dsred vector (a gift from Prof Laman, Department of Pathology, Cambridge) was used as a template to sub-clone WT and mutant FBXO7 constructs (23) . The In-Fusion™ Advantage PCR Cloning Kit (Clontech) was used to clone isoform 1 and isoform 2 WT FBXO7 into pcDNA3-myc/His vector or pcDNA3-GFP vector (Addgene plasmid 13031) which was developed by Dr Doug Golenbock. The pCMV6-XL5-FBXO7 (Plasmid ID SC112556) was purchased from OriGene Technologies, Inc., USA. The WT human PARKIN expression vector pRK5-HA-PARKIN used in this study was purchased from Addgene (Plasmid 17613, deposited by Ted Dawson) (48) . FBXO7 mutants (R498X, R378G and T22M) and PARKIN R275W mutant were created based on the template of pcDNA3-FBXO7-GFP and pRK5-HA-PARKIN plasmids respectively by PCR-based technique using QuickChange sitedirected mutagenesis kit (Stratagene, USA). Primers used for cloning of WT FBXO7 and creation of mutant FBXO7 were summarized in Supplementary Material, Table S1 . The ubiquitin plasmids [ pRK5-HA-Ubiquitin-KO (17603, all Lysine residues were mutated to Alanine, so substrates can only be mono-ubiquitinated instead of being poly-ubiquitinated), pRK5-HA-Ubiquitin-WT (17608)] were purchased from Addgene deposited by Ted Dawson (49) . The pRK5-HA-Ubiquitin-KO plus G76V vector was created based on the template pRK5-HA-Ubiquitin-KO using QuickChange site-directed mutagenesis kit (Stratagene, USA). The mitochondria targeting Mito-RFP plasmid was constructed by cloning of N terminal mitochondria targeting sequence (MTS) and transmembrane domain (TM) of human PINK1 (1-150 amino acid) into pcDNA3-mRFP plasmid (Addgene plasmid, 13032, developed by Dr Doug Golenbock) (50) . Scramble shRNA was purchased from Addgene (Plasmid 1864) deposited by David Sabatini (50) . The FBXO7 shRNA plasmids for human (TRCN vectors) or mice (GIPZ vectors) FBXO7 knock down were purchased from Open biosystem. The pLX304-PHB plasmid ( plasmid ID: HsCD00441072) was purchased from DNASU, USA. All cloned or created mutant constructs were sequenced using BigDye ® Terminator v3.1 cycle sequencing kit (Life Technologies) before transfection into cells.
Cell lines
The protocol to create human dopaminergic SH-SY-5Y LRRK2 stable cell lines used in the current study had been reported previously (5) . Briefly, SH-SY-5Y cells were transfected with pcDNA3.1 vector, pcDNA3.1-LRRK2-WT or pcDNA3.1-LRRK2-G2019S vector respectively using the lipofectamine reagents. After transfection, cells were treated with selection medium containing 0.6 g/l w/v G418 antibiotics (Promega) for 2-3 weeks before resistant cells were separated by serial dilution and allowed to grow from single cells. The stably transformed clones were verified by real-time RT-PCR and western blot analysis. Cells were maintained at 37°C in 5% CO 2 incubator with 0.4 g/l w/v G418. Human skin fibroblast cells from PD patients were purchased from the Coriell Institute for Medical Research, USA. Fibroblast cells were cultured and maintained in DMEM with 20% FBS at 37°C in 5% CO 2 incubator before experiments.
Transgenic animals
Transgenic mutant LRRK2 G2019S mice were provided by The Jackson Laboratory (#009604, B6.Cg-Tg (LRRK2*G2019S)2Yue/J). The transgenic and non-transgenic mice were maintained in accordance with institutional guidelines, and all protocols were approved through the Institutional Animal Care and Use Committee (IACUC) of the National Neuroscience Institute, Tan Tock Seng Hospital. The mice were maintained in a pathogen-free facility and exposed to a 12-h light/dark cycle with food and water. The hippocampus, cortex, striatum and midbrain samples were isolated from 12-month-old transgenic and non-transgenic control mice for further experimental analysis.
Primary cortical neuron culture
Embryonic day 16.5 female mice were euthanized with ketamine. Uteri were removed and individual fetuses were extracted and placed in sterile petri dish filled with sterile dissection medium [DM, HEPES-buffered Hanks' balanced salt solution (HBSS) without calcium or magnesium]. Cortex tissue was removed; trypsin was added into DM to a final concentration of 0.25%. After incubation with trypsin for 20 min at 37°C with slow agitation, tissue pieces were washed with 4 ml seeding medium (DMEM supplemented with 5% FBS plus antibiotics) to neutralize the remaining enzyme. The last wash was discarded and 4 ml of ice-cold seeding medium with 0.1 mg/ml DNase I was added before cells were seeded on dishes or coverslips at the following density: 1 × 10 5 cells per well for 4-well-plate and 1 × 10 6 cells per well for 6-well-plate. Medium was changed 4 h after seeding cells to feeding medium (Neurobasal containing Glutamax, B27, and antibiotic) and maintained in feeding medium for 7 days before further experiments.
Drosophila stocks, preparation and behavioral assays
Promoter lines containing elav-GAL4, ddc-GAL4 and 24B-GAL4 were obtained from Bloomington Stock Center (Bloomington, IN, USA). WT FBXO7 transgenic lines (W;P{UAS-Fbxo7.WT}(II) and W;P{UAS-Fbxo7.WT}attp.ZH-51C(II)) were gifts from Prof Alexander J Whitworth (MRC Centre for Developmental and Biomedical Genetics, Sheffield S10 2TN, UK). Flies were routinely raised at 25°C on cornmeal media that were replaced every 3 days. For longevity experiments, day-old flies were transferred to fresh media every 3 days. The lifespan was assessed by monitoring survival of 50 flies in five cohorts for each genotype. The triplicate cohorts of 50 flies per genotype were monitored for survival daily. For the climbing assay, motor ability was assessed at 15 min interval using the negative geotaxis assay. Briefly, 3 cohorts of 20 female and age-matched control flies were anesthetized and placed in a vertical plastic column (length, 25 cm; diameter, 1.5 cm). After a 2 h recovery period, flies were tapped to the bottom and the percentage of flies that climb to or above the top column line in 1 min was calculated. Triplicate trials were performed in each experiment at 15 min interval.
Human postmortem brain samples from AD and PD patients 
Transmission electron microscopy analysis
For transmission electron microscopy, adult thoraces of flies cultured for 40 days were hemisected, fixed overnight at 4°C in 2% paraformaldehyde, 3% glutaraldehyde in 0.1  phosphate buffer, pH 7.4. Tissues were postfixed in 2% osmium tetroxide for 1.5 h, dehydrated in ethanol-acetone series then embedded in araldite. Ultrathin sections were observed under Jeol Jem1010. Ultrathin sections were picked up onto copper slot grids, stained with uranyl acetate and lead citrate then observed under Jeol jem1010 and photographed (Peabody, MA, USA).
Drug administration
After cells were transfected with WT or mutant FBXO7 or FBXO7 shRNA for 6 h, cells were treated with different concentration of H 2 O 2 or DA and further incubated for 24 h at 37°C prior to analysis of cell viability or FBXO7 aggregation. To study the protective effects of GSH against aggregate-formation and cell viability decline, cells were transfected with WT or mutant FBXO7 and 500 µ GSH was added. Cells were further cultured for 2 days before protein aggregation and cell viability were analyzed. To study aggregation formation of endogenous FBXO7 induced by stressors, human or mice cells were treated with different concentrations of DA, H 2 O 2 , FCCP or Rotenone for different periods of time before FBXO7 protein aggregation or cell fractionation was performed. To study the inhibition of endogenous FBXO7 aggregate formation in human LRRK2 stable SH-SY-5Y dopaminergic cells or fibroblast cells from PD patients, cells were cultured in the presence or absence of 500 µ GSH or 300 µ COQ10 for 3 days before harvested for western blot analysis. To study the influence of FCCP-induced mitophagy by overexpression of PARKIN or FBXO7, cells were transfected with WT or mutant FBXO7 or PARKIN and treated with different concentration of FCCP for 2 h before mitophagy was analyzed. Unless specifically stated, all chemicals were purchased from Sigma-Aldrich.
MTT cell viability assay
Cell viability was monitored by MTT cell viability assay as previously described (52) . Briefly, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma) was prepared as 2 mg/ml stock solution in 1 × phosphate-buffered saline (1 × PBS) and stored at 4°C. The MTT/DMEM solution (15% v/v of 2 mg/ml MTT stock solution mixed with 85% v/v DMEM) was prepared freshly. Cells in 24-well dishes were washed with PBS and incubated in 500 µl of MTT/DMEM solution in the dark at 37°C for 3 h. The solution was then aspirated without disrupting the cells and 500 µl of solubilizing solution [0.04  hydrochloric acid/isopropanol plus 3% w/v sodium dodecyl sulfate (SDS)] was added and mixed well. The plates were incubated at room temperature for 1 h in the dark. The solution optical density (OD) was then measured at 595 nm using a spectrophotometer (Elisa Reader Spectra Max 340) in a 96-well plate (Iwaki).
PI-Hoechst dual fluorescent dyes staining of cell viability
The PI-Hoechst dual fluorescent dyes staining protocol was derived and modified from calcein-PI dual fluorescent cell viability detection protocol. The aim to introduce Hoechst dye into the assay is to prevent any adverse influence on final PI fluorescent intensity due to variance of cell numbers among respective groups. In brief, 3.5 × 10 4 cells were plated into each well of 96-well μClear tissue culture-treated black plate (Greiner). After transfection and drugs administration, 15 µl of Opti-MEM containing PI (2.5 µg/ml) and Hoechst (2 µg/ml) were added to each well. After incubation of cells at 37°C for 30 min in the dark, the fluorescence intensity PI and Hoechst was measured by Tecan Infinite M200 microplate reader at different wavelengths: 530 nm excitation and 620 nm emission for PI and 335 nm excitation and 460 nm emission for Hoechst. The relative fluorescent intensity of PI was acquired via division of PI readings with Hoechst readings of each well, respectively. Cells without any treatment were set as control group. The cell viability of other groups was expressed as the relative PI fluorescent intensity (% control).
Western blot analysis
Cells were collected in lysis buffer [100 m HEPES pH 7. 
Quantitative analysis of western blot data
Quantitative analysis of the densities of protein bands in western blot gels was carried out by densitometric analysis using the image software Bandscan 4.30. The ratio of the densities of respective protein bands in control lanes in western blot gels was set as 50%. The relative densities of protein bands of other lanes were expressed as the ratio of densities, after automatic comparison with the ratio of densities of control lanes by the software. 
Analysis of FBXO7 protein aggregates by western blot analysis
Quantitative real-time RT-PCR
Expression levels of FBXO7 in human dopaminergic SH-SY-5Y and human fibroblast cells were analyzed using real-time quantitative RT-PCR. Total RNA was isolated using NucleoSpin RNA II (Macherey-Nagel). A two-step quantitative RT-PCR was carried out. Reverse transcription was performed with Maxima First Strand cDNA synthesis kit for RT-qPCR (Fermentas); 1 µg RNA sample was used for each reverse transcription. RT-qPCR primers used in this study are as follows: forward primer (GAGGCTGCGGG TGCGGCT) and reverse primer (TCAAGTCCCCAGAAACAA). All real-time PCR reactions were performed using the CFX96 real-time PCR detection system (Bio-Rad Laboratories) and the amplifications were done using Maxima SYBR Green/Fluorescein qPCR master mix (2X) (Fermentas). Thermal cycling conditions comprised incubation at 50°C for 2 min followed by an initial denaturation step at 95°C for 10 min, 40 cycles at 95°C for 15 s and 60°C for 45 s. Experiments were carried out in triplicate for each data point. Expression data were normalized to the geometric mean of housekeeping gene β-actin to control the variability in expression levels. The relative quantification in gene expression was determined using the 2 −ΔΔCT method (53) . The expression levels of WT1 FBXO7 protein in control cells without any stresses were set as 100% and FBXO7 expressions of other groups were expressed as % of control cells.
Monitoring GFP-tagged FBXO7 overexpression by fluorescent spectrophotometry
After transfection of cells with GFP-tagged WT or mutant FBXO7 overnight, cells were harvested and lysed in M-PER mammalian extraction buffer (Thermo Scientific). After determination of protein concentration, 400 µg protein lysates in 150 µl M-PER buffer were transferred into black flat bottom 96-well plates (Nunc). Samples were analyzed with Infinite M200 Microplate Reader (Tecan) at excitation and emission wavelength at 488 and 509 nm respectively for EGFP fluorescence.
Immunocytochemistry
After cells on cover slips were stressed with neurotoxins, they were fixed with 4% p-formaldehyde at room temperature for 20 min, washed with 1 × PBS containing 0.3% (v/v) Triton-X for three times 5 min each, blocked with 5% (w/v) bovine serum albumin (BSA) at room temperature for 1 h. Cells were then incubated with primary anti-FBXO7 (1:100, Abnovas); anti-TOM20 (1:100, Sigma) or anti-4-HNE (1:100, antibodies online) antibody for 1 h at room temperature, followed by incubation of secondary Alexa Fluor ® 488 chicken anti-rabbit IgG (1:500, Molecular Probes)
or Alexa Fluor ® 594 chicken anti-rabbit IgG antibodies at room temperature for 1 h. After washing, cover slips were mounted on slides using 10 µl of mounting medium containing 0.2% (w/v) Hoechst dye (Invitrogen). Slides were dried for 24 h before observation and photographed under Axio Imager.M1 fluorescence microscope (Carl Zeiss) or LSM710 Carl Zeiss upright confocal microscope (Zeiss).
Quantitative detection of ROS levels in living cells
In this study, we have developed a novel protocol that can detect the ROS levels in living cells using the RedoxSensor Red CC-1 dye (R14060, Invitrogen). Briefly, cells were seeded onto 6-well plates 1 day before experiments. After transfection or challenge with neurotoxin stressors, cells were incubated with 1 µ RedoxSensor Red CC-1 for 10 min at 37°C. Cells were then washed with 1 × PBS three times before cells were harvested and resuspended in PBS buffer. About 2 × 10 5 cells were transferred into each well of black color flat bottom 96-well plates (Nunc), and samples were measured by the Infinite M200 Microplate Reader (Tecan) at excitation and emission wavelength at 540 and 600 nm respectively for RedoxSensor Red CC-1 fluorescence.
Mitochondria potential assay
After transfected cells were incubated in Opti-MEM (Invitrogen) containing 1 µ tetramethylrhodamine ethyl ester perchlorate (TMRE) for 30 min at 37°C in a CO 2 incubator, cells were collected and resuspended. A total of 100 µl aliquots were transferred into black flat bottom 96-well plates (Nunc). Samples were analyzed with Infinite M200 Microplate Reader (Tecan) at excitation and emission wavelength at 549 and 575 nm respectively for TMRE fluorescence. The mitochondrial potential of control cells transfected with GFP was set as 100% and mitochondrial potential of cells transfected with respective FBXO7 vectors was expressed as % of the mitochondrial potential of control cells.
Cell fractionation
Cell fractionation experiments were performed using the Cell Fractionation Kit from Mitosciences in accordance with the manufacturer's protocol. After H 2 O 2 or FCCP challenge, the cells were harvested. Mitochondrial and nuclear components were separated and harvested. The purity of each fraction was tested by western blot analysis using anti-PARP (1:1000, Abcam) or anti-cytochrome-c (1:1000, Abcam) antibodies. The content of endogenous FBXO7 in nucleus or mitochondria in the presence or absence of stresses was analyzed by western blot analysis, respectively. 
NAO-based quantitative mitophagy analysis
ABTS cation decolorization assay
The monitoring of 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS) radical scavenging activity of chemicals was measured by the ABTS cation decolorization assay as described by Re et al. (54) give an absorbance of 0.7 ± 0.01 at 734 nm. Chemicals in solutions (1 ml) were allowed to react with 2 ml of the ABTS •+ solution and the absorbance was measured at 734 nm after 1 min. The group in the absence of any reductants was set as control group. The results were expressed as % of control at OD 734 nm.
Statistical analysis
Statistical analyses were conducted using one-way or two-way ANOVA followed by post hoc Student's t-test using software Minitab 14. 
Supplementary Material
Supplementary Material is available at HMG online.
